[Lutein inhibits the adhesion, invasiveness and metastasis of human prostate cancer PC-3M cells]

Zhonghua Nan Ke Xue. 2023 Mar;29(3):210-217.
[Article in Chinese]

Abstract

Objective: To explore the effects of lutein on the adhesion, invasiveness and metastasis of human prostate cancer PC-3M cells and its action mechanism.

Methods: We divided human prostate cancer PC-3M cells into a control, a low-dose lutein, a medium-dose lutein and a high-dose lutein group, and treated them with 0, 10, 20 and 40 μmol/L lutein, respectively. Then we examined the adhesion of the cells to matrix by cell adhesion assay and the changes in cell pseudopodia by Phalloidin staining, detected the expressions of paxillin, matrix metalloproteinase 2 (MMP-2), MMP-9, recombinant tissue inhibitors of metalloproteinase 1 (TIMP-1), E-cadherin, N-cadherin and vimentin by Western blot, determined the invasiveness and migration of the cells by scratch and Transwell assays, and observed their dynamic movement by high-intension imaging.

Results: Compared with the control, the lutein intervention groups showed significant reduction in the number of the cells adhered to matrix, the number of cell pseudopodia, the expressions of paxillin, MMP-2, MMP-9, N-cadherin and vimentin, the rates of migration, invasion and metastasis, and the distances of displacement and movement of the cells. However, the expressions of TIMP-1 and epithelial-mesenchymal transition-related E-cadherin were upregulated significantly.

Conclusion: Lutein can inhibit cell adhesion, reduce the expressions of MMPs, and suppress cell invasion and migration by inhibiting the process of epithelial-mesenchymal transition.

Keywords: prostatic cancer; lutein; cell adhesion; invasion; metastasis.

Publication types

  • English Abstract

MeSH terms

  • Cadherins / metabolism
  • Cadherins / pharmacology
  • Cadherins / therapeutic use
  • Cell Line, Tumor
  • Cell Movement
  • Epithelial-Mesenchymal Transition
  • Humans
  • Lutein / metabolism
  • Lutein / pharmacology
  • Lutein / therapeutic use
  • Male
  • Matrix Metalloproteinase 2* / metabolism
  • Matrix Metalloproteinase 2* / pharmacology
  • Matrix Metalloproteinase 9 / metabolism
  • Matrix Metalloproteinase 9 / pharmacology
  • Matrix Metalloproteinase 9 / therapeutic use
  • Neoplasm Invasiveness
  • Paxillin / metabolism
  • Paxillin / pharmacology
  • Prostatic Neoplasms* / pathology
  • Tissue Inhibitor of Metalloproteinase-1 / metabolism
  • Tissue Inhibitor of Metalloproteinase-1 / pharmacology
  • Tissue Inhibitor of Metalloproteinase-1 / therapeutic use
  • Vimentin / metabolism

Substances

  • Matrix Metalloproteinase 2
  • Paxillin
  • Lutein
  • Matrix Metalloproteinase 9
  • Vimentin
  • Tissue Inhibitor of Metalloproteinase-1
  • Cadherins